Compound useful for the treatment of degenerative and inflammatory diseases
Inventors
Menet, Christel Jeanne Marie • SMITS, Koen Kurt
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12042498-B2
Publication Date
2024-07-23
Expiration Date
Abstract
A novel compound able to inhibit JAK is disclosed, that comprises a compound of Formula I:The compound may be prepared as a pharmaceutical composition, and may be used for the treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.
Core Innovation
The invention relates to a JAK inhibitor of Formula (I), including JAK1/JAK2 inhibition. The compound(s) of Formula (I) are presented as useful for treating multiple inflammatory, autoimmune, and proliferative diseases, including transplantation rejection and cartilage/IL-6–related diseases. The document positions the invention as providing improved in vivo potency for the treated conditions and potential for lower dosage.
A key aspect of the disclosure is the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in methods of treatment. The document further provides pharmaceutical composition coverage, including a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt.
The document also addresses disease areas linked to IL-6 and inflammatory signaling, including hypersecretion of IL-6 and related cartilage turnover impairment, congenital cartilage malformations, and other inflammatory/autoimmune/proliferative indications. Example disease statements explicitly include ulcerative colitis, rheumatoid arthritis, osteoarthritis, COPD, asthma, Crohn’s disease, Castleman’s disease, and mesangial proliferative glomerulonephritis.
Claims Coverage
The provided claim set contains two independent claims, both directed to methods of treating ulcerative colitis. Across these independent claims, the inventive coverage centers on administering a compound of Formula I (or a pharmaceutically acceptable salt) either directly or as part of a pharmaceutical composition containing a pharmaceutically acceptable carrier.
Ulcerative colitis treatment by administering a Formula I compound
Administering an amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, sufficient to effect treatment of ulcerative colitis.
Ulcerative colitis treatment via a pharmaceutical composition containing a Formula I compound
Administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, sufficient to effect treatment of ulcerative colitis.
The independent claims broadly cover ulcerative colitis treatment using Formula I JAK inhibitor compounds either administered directly or provided within a pharmaceutical composition containing a pharmaceutically acceptable carrier.
Stated Advantages
Improved in vivo potency.
Potential for lower dosage.
Documented Applications
Treatment of ulcerative colitis by administering a compound of Formula I (or a pharmaceutically acceptable salt).
Treatment of ulcerative colitis using a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of Formula I (or a pharmaceutically acceptable salt).
Treatment of inflammatory, autoimmune, and proliferative diseases, including transplantation rejection and cartilage/IL-6–related diseases.
Treatment areas explicitly mentioned in the document include rheumatoid arthritis, osteoarthritis, COPD, asthma, Crohn’s disease, Castleman’s disease, and mesangial proliferative glomerulonephritis.
Interested in licensing this patent?